

---

## Product Data Sheet

---

Product Name: Motavizumab

Cat. No.: GC68286

### Chemical Properties

Cas. No. 677010-34-3

Formula M.Wt

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Motavizumab (MEDI-524) is an anti-human **RSV (respiratory syncytial virus)** monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research<sup>[1]</sup>.

Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription<sup>[2]</sup>.

Motavizumab inhibits F protein-mediated cell-to-cell fusion<sup>[2]</sup>.

Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice<sup>[1]</sup>.

Animal Model: Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2<sup>[1]</sup>

Dosage: 1.25 mg in 0.1 ml of PBS/per mouse

Administration: Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

Result: Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1 $\alpha$ , IL-12p70, TNF- $\alpha$  and IFN- $\gamma$  and serum IL-10 and KC compared with RSV-infected untreated mice.

[1]. Mejías A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. *Virology*. 2007 Oct 25;4:109.

[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. *J Virol*. 2010 Aug;84(16):8132-40.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**